Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 989

1.

Design, synthesis and pre-clinical characterization of selective Factor D inhibitors targeting the alternative complement pathway.

Karki R, Powers J, Mainolfi N, Anderson K, Belanger DB, Liu D, Ji N, Jendza K, Gelin CF, Mac Sweeney A, Solovay C, Delgado O, Crowley M, Liao SM, Argikar UA, Flohr S, LaBonte LR, Lorthiois E, Vulpetti A, Brown A, Long D, Prentiss M, Gradoux N, de Erkenez A, Cumin F, Adams CM, Jaffee B, Mogi M.

J Med Chem. 2019 Apr 17. doi: 10.1021/acs.jmedchem.9b00271. [Epub ahead of print]

PMID:
30995036
2.

Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology.

Pediatr Nephrol. 2019 Apr 15. doi: 10.1007/s00467-019-04233-7. [Epub ahead of print]

PMID:
30989342
3.

[HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].

Mancini A, Ardissino G, Angelini P, Giancaspro V, La Raia E, Nisi M, Proscia A, Tarantino G, Vitale O, D'elia F.

G Ital Nefrol. 2019 Apr;36(2). pii: 2019-vol2. Italian.

PMID:
30983177
4.

Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.

Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Frémeaux-Bacchi V, Fakhouri F.

Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30165-6. doi: 10.1016/j.kint.2019.01.023. [Epub ahead of print]

PMID:
30982675
5.

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.

Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA.

BMC Nephrol. 2019 Apr 10;20(1):125. doi: 10.1186/s12882-019-1314-1.

6.

Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.

de Ville de Goyet M, Detaille T, Godefroid N.

J Pediatr Hematol Oncol. 2019 Mar 29. doi: 10.1097/MPH.0000000000001449. [Epub ahead of print]

PMID:
30933023
7.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. doi: 10.1073/pnas.1820892116. Epub 2019 Mar 29.

8.

Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.

Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC.

Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30050-X. doi: 10.1016/j.kint.2019.01.009. [Epub ahead of print]

PMID:
30910380
9.
10.

Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan.

Tseng MH, Tsai JD, Tsai IJ, Huang SM, Huang JL, Fan WL, Lee HJ, Wu TW, Lin SH.

Clin Chim Acta. 2019 Mar 21;494:143-150. doi: 10.1016/j.cca.2019.03.1623. [Epub ahead of print]

PMID:
30905589
11.

Postpartum Renal Cortical Necrosis Is Associated With Atypical Hemolytic Uremic Syndrome in Developing Countries.

Ramachandran R, Nayak S, Anakutti HP, Yadav AK, Nada R, Jain V, Gupta KL, Jha V.

Kidney Int Rep. 2018 Nov 28;4(3):420-424. doi: 10.1016/j.ekir.2018.11.012. eCollection 2019 Mar.

12.

Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome.

El Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J, Aulagnon F, Matignon M, Rondeau E, Mesnard L, Halimi JM, Frémeaux-Bacchi V.

Haematologica. 2019 Mar 19. pii: haematol.2019.216903. doi: 10.3324/haematol.2019.216903. [Epub ahead of print]

13.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019 Mar 19:1-7. doi: 10.1159/000497823. [Epub ahead of print]

PMID:
30889567
14.

Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other?

Timmermans SAMEG, van Paassen P; Limburg Renal Registry.

Nephron. 2019 Mar 14:1-5. doi: 10.1159/000497779. [Epub ahead of print]

15.

Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.

Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R.

Curr Opin Nephrol Hypertens. 2019 May;28(3):278-287. doi: 10.1097/MNH.0000000000000499.

PMID:
30865166
16.

Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.

Trojnar E, Józsi M, Szabó Z, Réti M, Farkas P, Kelen K, Reusz GS, Szabó AJ, Garam N, Mikes B, Sinkovits G, Mező B, Csuka D, Prohászka Z.

Front Immunol. 2019 Feb 25;10:240. doi: 10.3389/fimmu.2019.00240. eCollection 2019.

17.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Mar 6. pii: S0272-6386(19)30003-4. doi: 10.1053/j.ajkd.2018.11.012. [Epub ahead of print]

PMID:
30851964
18.

Seizure as the Presenting Symptom for Atypical Hemolytic Uremic Syndrome.

Chan S, Weinstein AR.

J Emerg Med. 2019 Apr;56(4):441-443. doi: 10.1016/j.jemermed.2018.12.034. Epub 2019 Feb 27.

PMID:
30826084
19.

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D.

Blood Adv. 2019 Feb 26;3(4):621-632. doi: 10.1182/bloodadvances.2018025692.

20.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Feb 13. doi: 10.1007/s40262-019-00742-8. [Epub ahead of print] Review.

PMID:
30758736

Supplemental Content

Loading ...
Support Center